mPEG-DMPE, MW 550-40k

Name: mPEG-DMPE, MW 550-40k
Brand: BOC Sciences
Rating: 5 (1 reviews)

Cat No.: BPG-0138

4.5

mPEG-DMPE is a phospholipid PEG derivative, which has broad application in targeted drug delivery by modifying with antibodies and peptides on surface. Also it increases the solubility of drugs.

Category	mPEG-DMPE
Molecular Weight	Customizable
Storage	-20°C for long-term preservation, keep in dry and avoid sunlight. Avoid repeated freezing and thawing.

Structure of mPEG-DMPE, MW 550-40k

Ordering Information

*For research and manufacturing use only. We do not sell to patients.

Fast-Track Access to Precise Molecular Weight Products

Professional Solutions for Molecular Research

Catalog	Molecular Weight	Availability	actions
BPG-0138-1	mPEG-DMPE, MW 550	In stock	Inquiry
BPG-0138-2	mPEG-DMPE, MW 1k	In stock	Inquiry
BPG-0138-3	mPEG-DMPE, MW 2k	In stock	Inquiry
BPG-0138-4	mPEG-DMPE, MW 5k	In stock	Inquiry
BPG-0138-5	mPEG-DMPE, MW 10k	In stock	Inquiry
BPG-0138-6	mPEG-DMPE, MW 20k	In stock	Inquiry
BPG-0138-7	mPEG-DMPE, MW 30k	In stock	Inquiry
BPG-0138-8	mPEG-DMPE, MW 40k	In stock	Inquiry

cGMP Capacity

cGMP-compliant manufacturing options
Comprehensive QC testing with COA, MSD
From mg and g to kg-scale production
In-stock supply in the US and Europe
Global supply & fast worldwide delivery
One-stop PEGylation services
Custom PEG reagents synthesis
Click chemistry reagents
Bioconjugation & drug delivery
Trusted by 100+ research institutions

Popular Publications Citing BOC Sciences Products

Specification
Key Product Attributes
Reaction & Conjugation Properties
References

Synonyms	mPEG-Double nutmeg phosphatidylethanolamine
Solubility	Soluble in water, DMSO and DMF. Freshly prepared before use.

PEGType	Lipid PEG
PEGArchitecture	Linear
LipidType	DMPE

ResearchUse

Liposome / LNP Surface Functionalization

1. Modi, Sweta, and Bradley D. Anderson. Determination of drug release kinetics from nanoparticles: overcoming pitfalls of the dynamic dialysis method. Molecular pharmaceutics, 2013, 10(8): 3076-3089.
2. Eliaz, Rom Ezer, et al. Composition and dosage form comprising an interferon particle formulation and suspending vehicle. U. S. Patent No. 7,731,947. 8 Jun. 2010.